论文部分内容阅读
疱疹病毒感染的发病率很高,偶而使免疫抑制病人死亡。在Hodgkin氏疾病的某些阶段约20%的病人会发生带状疱疹,其中三分之一病由于感染播散可能会导致威胁生命的合併症。经受了骨髓移植手术的病人对此病特别易感。本文作者报告了用Acyclovir治疗免疫抑制病人的各种疱疹病毒感染的临床体会。 Acyclovir(9—[2—羟基乙氧基甲基)鸟嘌呤),以前称为Acycloguanosine,是一种带有一个无环侧链的鸟嘌呤衍生物。经试管和实验动物证明为对疱疹病毒具有高度抵抗作用的新抗病毒制剂。
The incidence of herpes virus infection is high, occasionally killing immunosuppressed patients. About 20% of patients in some stages of Hodgkin’s disease develop shingles, and one third of them may spread life-threatening complications due to infection. Patients who have undergone a bone marrow transplant are particularly susceptible to the disease. The authors report on the clinical experience with Acyclovir in the treatment of herpes simplex virus infections in immunosuppressed patients. Acyclovir (9- [2-hydroxyethoxymethyl) guanine), formerly known as Acycloguanosine, is a guanine derivative with an acyclic side chain. In vitro and laboratory animals have proven to be highly resistant to the herpes virus, a new anti-viral agent.